BRAF and melanoma: KEYNOTE-002 study was a randomized phase II multicenter trial in which advanced melanoma patients with progression after ipilimumab and/or BRAF/MEK inhibitors were randomized to pembrolizumab 2 mg/kg or 10 mg/kg every 3 weeks or investigator-choice chemotherapy.